Retatrutide, from Soma Pharmaceuticals , is gaining significant attention as a innovative treatment for obesity regulation. This unique drug merges the activity of a GLP-1 receptor agonist and a GIP receptor activator , intended to simply promote reduced body fat but also improve underlying metab